- Home
- MPA vs IPHA Comparison
MPA vs IPHA Comparison
Compare MPA & IPHA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MPA
- IPHA
- Stock Information
- Founded
- MPA 1992
- IPHA 1999
- Country
- MPA United States
- IPHA France
- Employees
- MPA N/A
- IPHA N/A
- Industry
- MPA Finance Companies
- IPHA Biotechnology: Pharmaceutical Preparations
- Sector
- MPA Finance
- IPHA Health Care
- Exchange
- MPA Nasdaq
- IPHA Nasdaq
- Market Cap
- MPA 148.2M
- IPHA 160.1M
- IPO Year
- MPA N/A
- IPHA 2019
- Fundamental
- Price
- MPA $11.33
- IPHA $1.82
- Analyst Decision
- MPA
- IPHA Strong Buy
- Analyst Count
- MPA 0
- IPHA 3
- Target Price
- MPA N/A
- IPHA $5.00
- AVG Volume (30 Days)
- MPA 25.2K
- IPHA 26.2K
- Earning Date
- MPA 01-01-0001
- IPHA 09-17-2025
- Dividend Yield
- MPA 3.83%
- IPHA N/A
- EPS Growth
- MPA N/A
- IPHA N/A
- EPS
- MPA N/A
- IPHA N/A
- Revenue
- MPA N/A
- IPHA $14,839,695.00
- Revenue This Year
- MPA N/A
- IPHA $22.29
- Revenue Next Year
- MPA N/A
- IPHA $43.84
- P/E Ratio
- MPA N/A
- IPHA N/A
- Revenue Growth
- MPA N/A
- IPHA N/A
- 52 Week Low
- MPA $9.87
- IPHA $1.29
- 52 Week High
- MPA $12.21
- IPHA $3.51
- Technical
- Relative Strength Index (RSI)
- MPA 47.37
- IPHA 37.75
- Support Level
- MPA $11.33
- IPHA $1.95
- Resistance Level
- MPA $11.50
- IPHA $2.40
- Average True Range (ATR)
- MPA 0.12
- IPHA 0.11
- MACD
- MPA -0.01
- IPHA -0.04
- Stochastic Oscillator
- MPA 16.00
- IPHA 10.77
About MPA Blackrock MuniYield Pennsylvania Quality Fund
Blackrock Muniyield Pennsylvania Quality Fund is a closed-end fund with an investment objective to provide shareholders with as high a level of current income exempt from U.S. federal and Pennsylvania income taxes as is consistent with its investment policies and prudent investment management. The Fund seeks to achieve its investment objective by investing, as a fundamental policy, at least 80% of an aggregate of the Fund's net assets and the proceeds of any borrowings for investment purposes, in a portfolio of municipal obligations issued by or on behalf of the State of Pennsylvania, its political subdivisions, agencies, and instrumentalities and by other qualifying issuers.
About IPHA Innate Pharma S.A. ADS
Innate Pharma SA is a clinical-stage biotechnology company. It is engaged in developing immunotherapies for cancer patients. Its approach is to harness the innate immune system through therapeutic antibodies and its ANKET (Antibody-based NK cell Engager Therapeutics) proprietary platform. The company's revenue results from payments received to research, collaboration, and licensing agreements signed with pharmaceutical companies. Its product pipeline includes lacutamab, monalizumab, IPH5201, IPH5301, IPH6101, IPH62, IPH6401 and IPH6501.